ETF日报：各方面利好消息不断出现，创新药板块或存在盈利和估值抬升的可能，可关注创新药ETF

Market Overview - A-shares opened slightly lower and fluctuated before stabilizing, with the Shanghai Composite Index closing at 3997.56 points, down 0.25% [1] - The Shenzhen Component Index fell by 0.36%, and the ChiNext Index decreased by 0.51%, with over 3100 stocks declining [1] - The trading volume in both markets was approximately 2 trillion, slightly lower than the previous day [1] Sector Performance - Software and innovative drug sectors showed weaker performance, while chemical and photovoltaic sectors gained due to rising raw material prices and anti-involution policies [1] - The innovative drug ETF from Guotai (589720) has seen continuous inflows, totaling over 200 million in the last five trading days [7] Investment Sentiment - Concerns about the "AI bubble" and its potential impact on A-shares have emerged, with investors questioning whether market corrections present opportunities or traps [1] - Despite fluctuations in the external market, the domestic market's valuation logic remains strong, with a clear investment outlook emerging [2] Future Outlook - The bull market is expected to continue, with new leading sectors likely to emerge during the rotation process [5] - The innovative drug sector is anticipated to see both profit and valuation increases, driven by positive industry news and AI's role in drug development [9][11] - The coal sector is experiencing a rebound, with recent price increases and inventory reductions providing support for near-term performance [15][17] Policy and Economic Factors - Ongoing policy developments are expected to improve macroeconomic expectations, supporting coal prices from both supply and demand sides [17] - The introduction of AI in drug development is likely to enhance efficiency and reduce costs, further boosting the innovative drug sector [12][13]